Bortezomib-induced survival signals and genes in human proximal tubular cells

Journal of Pharmacology and Experimental Therapeutics

Volumn 327, Issue 3, 2008, Pages 645-656

  Sarközi, Rita ^a   Perco, Paul ^b   Hochegger, Kathrin ^a   Enrich, Julia ^a   Wiesinger, Martin ^b   Pirklbauer, Markus ^a   Eder, Susanne ^a   Rudnicki, Michael ^a   Rosenkranz, Alexander R ^a   Mayer, Bernd ^b   Mayer, Gert ^a   Schramek, Herbert ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b Emergentec Biodevelopment GmbH   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

BAG 3 PROTEIN; BAG 5 PROTEIN; BORTEZOMIB; CASPASE 3; CASPASE 9; CELL PROTEIN; HEAT SHOCK PROTEIN 70; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL LEVEL; CELL PROTECTION; CELL SURVIVAL; CELL TYPE; CONTROLLED STUDY; DRUG SPECIFICITY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GENE EXPRESSION REGULATION; GENE INDUCTION; HUMAN; HUMAN CELL; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE CELL; KIDNEY TUBULE EPITHELIUM; MESANGIUM CELL; MICROARRAY ANALYSIS; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION;

EID: 57349152434     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.108.142604     Document Type: Article

References (40)

1. Adams J (2002) Proteasome inhibitors as new anticancer drugs. Curr Opin Oncol 14:628-634.
2. An J and Rettig MB (2007) Epidermal growth factor receptor inhibition sensitizes renal cell carcinoma cells to the cytotoxic effects of bortezomib. Mol Cancer Ther 6:61-69.
3. An J, Sun Y, Fisher M, and Rettig MB (2004) Maximal apoptosis of renal cell carcinoma by the proteasome inhibitor bortezomib is nuclear factor-κB dependent. Mol Cancer Ther 3:727-736.
4. Arya R, Mallik M, and Lakhotia SC (2007) Heatshock genes: integrating cell survival and death. J Biosci 32:595-610.
5. Batuman V (2007) Proximal tubular injury in myeloma. Contrib Nephrol 153:87-104.
6. Brazma A, Hingamp P, Quackenbush J, Sherlock G, Spellman P, Stoeckert C, Aach J, Ansorge W, Ball CA, Causton HC, et al. (2001) Minimum information about a microarray experiment (MIAME)-toward standards for microarray data. Nat Genet 29:365-371.
7. Calvaruso G, Giuliano M, Portanova P, De Blasio A, Vento R, and Tesoriere G (2006) Bortezomib induces in HepG2 cells IκBα degradation mediated by caspase-8. Mol Cell Biochem 287:13-19.
8. Calvaruso G, Giuliano M, Portanova P, Pellerito O, Vento R, and Tesoriere G (2007) Hsp72 controls bortezomib-induced HepG2 cell death via interaction with proapoptotic factors. Oncol Rep 18:447-450.
9. Chanan-Khan AA, Kaufman JL, Mehta J, Richardson PG, Miller KC, Lonial S, Munshi NC, Schlossman R, Tariman J, and Singhal S (2007) Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. Blood 109:2604-2606.
10. Ciechanover A and Schwartz AL (1998) The ubiquitin-proteasome pathway: the complexity and myriad functions of proteins death. Proc Natl Acad Sci U S A 95:2727-2730.
11. Cusack JC Jr, Liu R, Houston M, Abendroth K, Elliott PJ, Adams J, and Baldwin AS Jr (2001) Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-κB inhibition. Cancer Res 61:3535-3540.
12. Dai Y, Rahmani M, and Grant S (2003) Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK- and NF-kappaB-dependent process. Oncogene 22:7108-7122.
13. David E, Sun S-Y, Waller EK, Chen J, Khuri FR, and Lonial S (2005) The combination of the farnesyl transferase inhibitor lonafarnib and the proteasome inhibitor bortezomib induces synergistic apoptosis in human myeloma cells that is associated with down-regulation of p-AKT. Neoplasia 106:4322-4329.
14. Demartino GN and Gillette TG (2007) Proteasomes: machines for all reasons. Cell 129:659-662.
15. Dolcet X, Llobet D, Encinas M, Pallares J, Cabero A, Schoenenberger JA, Comella JX, and Matias-Guiu X (2006) Proteasome inhibitors induce death but activate NF-κB on endometrial carcinoma cell lines and primary culture explants. J Biol Chem 281:22118-22130.
16. Doong H, Vrailas A, and Kohn EC (2002) What's in the "BAG"? A functional domain analysis of the BAG-family of proteins. Cancer Lett 188:25-32.
17. Drexler HC (1997) Activation of the cell death program by inhibition of proteasome function. Proc Natl Acad Sci U S A 94:855-860.
18. Frankel A, Man S, Elliott P, Adams J, and Kerbel RS (2000) Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341. Clin Cancer Res 6:3719-3728.
19. Fujita T, Doihara H, Washio K, Ino H, Murakami M, Naito M, and Shimizu N (2007) Antitumor effects and drug interactions of the proteasome inhibitor bortezomib (PS341) in gastric cancer cells. Anticancer Drugs 18:677-686.
20. Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J, and Anderson KC (2001) The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 61:3071-3076.
21. Jagannath S, Durie BG, Wolf J, Camacho E, Irwin D, Lutzky J, McKinley M, Gabayan E, Mazumder A, Schenkein D, et al. (2005) Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol 129:776-783.
22. Kalia SK, Lee S, Smith PD, Liu L, Crocker SJ, Thorarinsdottir TE, Glover JR, Fon EA, Park DS, and Lozano AM (2004) BAG5 inhibits parkin and enhances dopaminergic neuron degeneration. Neuron 44:931-945.
23. Kastritis E, Anagnostopoulos A, Roussou M, Gika D, Matsouka C, Barmparousi D, Grapsa I, Psimenou E, Bamias A, and Dimopoulos MA (2007) Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents. Haemtologica 92:546-549.
24. Livak KJ and Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25:402-408.
25. Manning BD and Cantley LC (2007) AKT/PKB signaling: navigating downstream. Cell 129:1261-1274.
26. Meiners S, Ludwig A, Stangl V, and Stangl K (2008) Proteasome inhibitors: poisons and remedies. Med Res Rev 28:309-327.
27. Mohrbacher A and Levine AM (2005) Reversal of advanced renal dysfunction on bortezomib treatment in multiple myeloma patients (Abstract), in Proceedings of the Annual Meeting of the American Society of Clinical Oncology; 2005 May 13-17; Orlando, FL. Vol 24, pp 6714, American Society of Clinical Oncology, Alexandria, VA.
28. Nozza A, Siracisano L, and Armando S (2006) Bortezomib-dexamethasone combination in a patient with refractory multiple myeloma and impaired renal function. Clin Ther 28:953-959.
29. Ostermann E, Schrattbauer K, Ludwig H, Graf H (2006) Rapid recovery of kidney function in patients with multiple myeloma under bortezomib-combination therapy (Abstract). J Am Soc Nephrol 17:808A.
30. Perkins ND (2007) Integrating cell-signalling pathways with NF-κB and IKK function. Nat Rev Mol Cell Biol 8:49-62.
31. Rosati A, Ammirante M, Gentilella A, Basile A, Festa M, Pascale M, Marzullo L, Belisario MA, Tosco A, Franceschelli S, et al. (2007) Apoptosis inhibition in cancer cells: a novel molecular pathway that involves BAG3 protein. Int J Biochem Cell Biol 39:1337-1342.
32. Sarközi R, Miller B, Pollack V, Feifel E, Mayer G, Sorokin A, and Schramek H (2007) ERK1/2-driven and MKP-mediated inhibition of EGF-induced ERK5 signaling in human proximal tubular cells. J Cell Physiol 211:88-100.
33. Schramek H, Gstraunthaler G, Willinger CC, and Pfaller W (1993) Hyperosmolality regulates endothelin release by Madin-Darby canine kidney cells. J Am Soc Nephrol 4:206-213.
34. Schramek H, Schumacher M, and Pfaller W (1996) Sustained ERK-2 activation in rat glomerular mesangial cells: differential regulation by protein phosphatases. Am J Physiol 271:F423-F432.
35. Shringarpure R, Catley L, Bhole D, Burger R, Podar K, Tai YT, Kessler B, Galardy P, Ploegh H, Tassone P, et al. (2006) Gene expression analysis of B-lymphoma cells resistant and sensitive to bortezomib. Br J Haematol 134:145-156.
36. Torii S, Yamamoto Y, Tsuchiya Y, and Nishida E (2006) ERK MAP kinase in G1 cell cycle progression and cancer. Cancer Sci 97:697-702.
37. Traenckner EB, Wilk S, and Baeuerle PA (1994) A proteasome inhibitor prevents activation of NF-kappa B and stabilizes a newly phosphorylated form of I kappa B-alpha that is still bound to NF-kappa B. EMBO J 13:5433-5441.
38. Wang HQ, Liu HM, Zhang HY, Guan Y, and Du ZX (2008) Transcriptional upregulation of BAG3 upon proteasome inhibition. Biochem Biophys Res Commun 365: 381-385.
39. Wójcik C (1999) Proteasomes in apoptosis: villains or guardians? Cell Mol Life Sci 56:908-917.
40. Yu C, Rahmani M, Dent P, and Grant S (2004) The hierarchical relationship between MAPK signaling and ROS generation in human leukemia cells undergoing apoptosis in response to the proteasome inhibitor bortezomib. Exp Cell Res 295: 555-566.